PMS19 COST MINIMIZATION AND BUDGET IMPACT ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB, ETANERCEPT AND ABATACEPT IN RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL
May 1, 2008, 00:00
10.1016/S1098-3015(10)70821-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)70821-4/fulltext
Title :
PMS19 COST MINIMIZATION AND BUDGET IMPACT ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB, ETANERCEPT AND ABATACEPT IN RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70821-4&doi=10.1016/S1098-3015(10)70821-4
First page :
Section Title :
Open access? :
No
Section Order :
575